Amivantamab (Rybrevant®). HTA ID: 22004

Assessment Status NCPE Assessment Process Complete
HTA ID 22004
Drug Amivantamab
Brand Rybrevant®
Indication For the treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum-based therapy.
Assessment Process
Rapid review commissioned 17/01/2022
Rapid review completed 03/02/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of amivantamab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 23/02/2022
Pre-submission consultation with Applicant 28/03/2022
Full submission received from Applicant 30/08/2022
Preliminary review sent to Applicant 24/01/2023
NCPE assessment re-commenced 22/02/2023
Factual accuracy sent to Applicant 30/03/2023
NCPE assessment re-commenced 11/04/2023
NCPE assessment completed 28/04/2023
NCPE assessment outcome The NCPE recommends that amivantamab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

* This recommendation should be considered while also having regard to the criteria
specified in the Health (Pricing and Supply of Medical Goods) Act 2013.